OTC Market Tier
State Of Incorporation
Jurisdiction Of Incorporation United States
- Michele Paige, President, CEO
Fiscal Year End 12/31
Estimated Market Cap
- $16,561,490 as of Oct 24, 2008
Outstanding Shares 13,144,040 as of Apr 30, 2004
Number of Share Holders of Record 87 as of Mar 31, 2008
- Formerly=Cadus Pharmaceutical Corp. until 7-03
- New Issue=7-96 2,750,000 shs at $7 by Hambrecht & Quist et al.
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases.
Radus Reports Second Quarter 2008 Results
NEW YORK, Aug 14, 2008 /PRNewswire-FirstCall via COMTEX/ -- Cadus Corporation (OTC Bulletin Board: KDUS) announced today financial results for the second quarter ended June 30, 2008.
Revenues were $0 for the second quarter of 2008 and for the same period in 2007. Net income for the second quarter of 2008 was $52,795, compared to net income of $218,960 for the same period in 2007. Basic net income per share for the second quarter of 2008 was $0.00, compared to basic net income per share for the second quarter of 2007 of $0.02.
Revenues were $100,000 for the first six months of 2008 and for the same period in 2007. Net loss for the first six months of 2008 was $155,201, compared to a net loss of $339,509 for the same period in 2007. Basic net loss per share for the first six months of 2008 was $0.01, compared to a basic net loss per share for the same period in 2007 of $0.03.
As of June 30, 2008, Cadus had 13,144,040 shares outstanding.
This press release may contain forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's annual report on Form 10-K for the year ended December 31, 2007. These include risks and uncertainties relating to the company's ability to license its technologies to third parties, the company's capital needs and uncertainty of future funding, the company's history of operating losses, the unpredictability of patent protection and the risk of obsolescence of the company's technologies.
Condensed Consolidated Balance Sheets
June 30, December 31,
Cash and cash equivalents $13,536,436 $2,444,376
Short term investments 11,791,197 22,960,545
Interest receivable 31,394 102,518
Prepaid and other current assets 34,192 1,150
Total current assets 25,393,219 25,508,589
Investment in other ventures 190,868 186,790
Patents, net 507,617 550,834
Total assets $26,091,704 $26,246,213